Single-nucleotide variants in human CD81 influence hepatitis C virus infection of hepatoma cells

被引:7
作者
Alberione, Maria Pia [1 ,2 ]
Moeller, Rebecca [1 ,2 ]
Kirui, Jared [1 ,2 ]
Ginkel, Corinne [1 ,2 ]
Doepke, Mandy [1 ,2 ]
Stroeh, Luisa J. [3 ]
Machtens, Jan-Philipp [4 ,5 ,6 ]
Pietschmann, Thomas [1 ,2 ]
Gerold, Gisa [1 ,2 ,7 ]
机构
[1] Med Sch Hannover, Ctr Expt & Clin Infect Res, Inst Expt Virol, TWINCORE, Feodor Lynen Str 7, D-30625 Hannover, Germany
[2] Helmholtz Ctr Infect Res, Feodor Lynen Str 7, D-30625 Hannover, Germany
[3] Hannover Med Sch, Inst Virol, Hannover, Germany
[4] Forschungszentrum Julich, Inst Biol Informat Proc IBI 1, Mol & Zellphysiol, Julich, Germany
[5] Forschungszentrum Julich, JARA HPC, Julich, Germany
[6] Rhein Westfal TH Aachen, Inst Clin Pharmacol, Aachen, Germany
[7] Umea Univ, Virol & Wallenberg Ctr Mol Med WCMM, Dept Clin Microbiol, Umea, Sweden
关键词
Hepatitis C virus; HCV; Hepatocyte; Tetraspanin; CD81; Receptor; Single-nucleotide variant; Entry; Genetic variant; B TYPE-I; CULTURE SYSTEMS; ENVELOPE GLYCOPROTEIN; SIGNAL-TRANSDUCTION; GENETIC-VARIATION; ENTRY; RECEPTOR; HCV; BINDING; IMPACT;
D O I
10.1007/s00430-020-00675-1
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
An estimated number of 71 million people are living with chronic hepatitis C virus (HCV) infection worldwide and 400,000 annual deaths are related to the infection. HCV entry into the hepatocytes is complex and involves several host factors. The tetraspanin human CD81 (hCD81) is one of the four essential entry factors and is composed of one large extracellular loop, one small extracellular loop, four transmembrane domains, one intracellular loop and two intracellular tails. The large extracellular loop interacts with the E2 glycoprotein of HCV. Regions outside the large extracellular loop (backbone) of hCD81 have a critical role in post-binding entry steps and determine susceptibility of hepatocytes to HCV. Here, we investigated the effect of five non-synonymous single-nucleotide variants in the backbone of hCD81 on HCV susceptibility. We generated cell lines that stably express the hCD81 variants and infected the cells using HCV pseudoparticles and cell culture-derived HCV. Our results show that all the tested hCD81 variants support HCV pseudoparticle entry with similar efficiency as wild-type hCD81. In contrast, variants A54V, V211M and M220I are less supportive to cell culture-derived HCV infection. This altered susceptibility is HCV genotype dependent and specifically affected the cell entry step. Our findings identify three hCD81 genetic variants that are impaired in their function as HCV host factors for specific viral genotypes. This study provides additional evidence that genetic host variation contributes to inter-individual differences in HCV infection and outcome.
引用
收藏
页码:499 / 514
页数:16
相关论文
共 58 条
[11]   RNA Interference and Single Particle Tracking Analysis of Hepatitis C Virus Endocytosis [J].
Coller, Kelly E. ;
Berger, Kristi L. ;
Heaton, Nicholas S. ;
Cooper, Jacob D. ;
Yoon, Rosa ;
Randall, Glenn .
PLOS PATHOGENS, 2009, 5 (12)
[12]   In silico directed mutagenesis identifies the CD81/claudin-1 hepatitis C virus receptor interface [J].
Davis, Christopher ;
Harris, Helen J. ;
Hu, Ke ;
Drummer, Heidi E. ;
McKeating, Jane A. ;
Mullins, Jonathan G. L. ;
Balfe, Peter .
CELLULAR MICROBIOLOGY, 2012, 14 (12) :1892-1903
[13]   Impact of single nucleotide polymorphisms in the essential HCV entry factor CD81 on HCV infectivity and neutralization [J].
Deest, Maximilian ;
Westhaus, Sandra ;
Steinmann, Eike ;
Manns, Michael P. ;
von Hahn, Thomas ;
Ciesek, Sandra .
ANTIVIRAL RESEARCH, 2014, 101 :37-44
[14]   Natural history of hepatitis C: Its impact on clinical management [J].
Di Bisceglie, AM .
HEPATOLOGY, 2000, 31 (04) :1014-1018
[15]   ANIMAL-CELL MUTANTS DEFECTIVE IN GLYCOSAMINOGLYCAN BIOSYNTHESIS [J].
ESKO, JD ;
STEWART, TE ;
TAYLOR, WH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1985, 82 (10) :3197-3201
[16]   Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry [J].
Evans, Matthew J. ;
von Hahn, Thomas ;
Tscherne, Donna M. ;
Syder, Andrew J. ;
Panis, Maryline ;
Woelk, Benno ;
Hatziioannou, Theodora ;
McKeating, Jane A. ;
Bieniasz, Paul D. ;
Rice, Charles M. .
NATURE, 2007, 446 (7137) :801-805
[17]   HCV Broadly Neutralizing Antibodies Use a CDRH3 Disulfide Motif to Recognize an E2 Glycoprotein Site that Can Be Targeted for Vaccine Design [J].
Flyak, Andrew I. ;
Ruiz, Stormy ;
Colbert, Michelle D. ;
Luong, Tiffany ;
Crowe, James E., Jr. ;
Bailey, Justin R. ;
Bjorkman, Pamela J. .
CELL HOST & MICROBE, 2018, 24 (05) :703-+
[18]   Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance [J].
Ge, Dongliang ;
Fellay, Jacques ;
Thompson, Alexander J. ;
Simon, Jason S. ;
Shianna, Kevin V. ;
Urban, Thomas J. ;
Heinzen, Erin L. ;
Qiu, Ping ;
Bertelsen, Arthur H. ;
Muir, Andrew J. ;
Sulkowski, Mark ;
McHutchison, John G. ;
Goldstein, David B. .
NATURE, 2009, 461 (7262) :399-401
[19]   Quantitative Proteomics Identifies Serum Response Factor Binding Protein 1 as a Host Factor for Hepatitis C Virus Entry [J].
Gerold, Gisa ;
Meissner, Felix ;
Bruening, Janina ;
Welsch, Kathrin ;
Perin, Paula M. ;
Baumert, Thomas F. ;
Vondran, Florian W. ;
Kaderali, Lars ;
Marcotrigiano, Joseph ;
Khan, Abdul G. ;
Mann, Matthias ;
Rice, Charles M. ;
Pietschmann, Thomas .
CELL REPORTS, 2015, 12 (05) :864-878
[20]   The HCV, Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets [J].
Gerold, Gisa ;
Pietschmann, Thomas .
DIGESTIVE DISEASES, 2014, 32 (05) :525-537